These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 21161198)
1. Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients. Chen B; Zhang W; Gu Z; Li J; Zhang Y; Cai W Eur J Clin Pharmacol; 2011 Jun; 67(6):601-12. PubMed ID: 21161198 [TBL] [Abstract][Full Text] [Related]
2. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Qiu XY; Jiao Z; Zhang M; Zhong LJ; Liang HQ; Ma CL; Zhang L; Zhong MK Eur J Clin Pharmacol; 2008 Nov; 64(11):1069-84. PubMed ID: 18636247 [TBL] [Abstract][Full Text] [Related]
3. Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China. Meng XG; Guo CX; Feng GQ; Zhao YC; Zhou BT; Han JL; Chen X; Shi Y; Shi HY; Yin JY; Peng XD; Pei Q; Zhang W; Wang G; He M; Liu M; Yang JK; Zhou HH Acta Pharmacol Sin; 2012 Dec; 33(12):1563-70. PubMed ID: 23085740 [TBL] [Abstract][Full Text] [Related]
4. Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients. Zhang Y; Li JL; Fu Q; Wang XD; Liu LS; Wang CX; Xie W; Chen ZJ; Shu WY; Huang M Acta Pharmacol Sin; 2013 Apr; 34(4):555-60. PubMed ID: 23503472 [TBL] [Abstract][Full Text] [Related]
5. Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem. Wang Y; Wang C; Li J; Wang X; Zhu G; Chen X; Bi H; Huang M Eur J Clin Pharmacol; 2009 Mar; 65(3):239-47. PubMed ID: 18936931 [TBL] [Abstract][Full Text] [Related]
6. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Hu YF; Qiu W; Liu ZQ; Zhu LJ; Liu ZQ; Tu JH; Wang D; Li Z; He J; Zhong GP; Zhou G; Zhou HH Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1093-8. PubMed ID: 17042920 [TBL] [Abstract][Full Text] [Related]
7. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Rong G; Jing L; Deng-Qing L; Hong-Shan Z; Shai-Hong Z; Xin-Min N Transplant Proc; 2010 Nov; 42(9):3455-8. PubMed ID: 21094796 [TBL] [Abstract][Full Text] [Related]
8. Influence of the MDR1 haplotype and CYP3A5 genotypes on cyclosporine blood level in Chinese renal transplant recipients. Chen B; Zhang W; Fang J; Jin Z; Li J; Yu Z; Cai W Xenobiotica; 2009 Dec; 39(12):931-8. PubMed ID: 19925383 [TBL] [Abstract][Full Text] [Related]
9. Association of CYP3A4*1B genotype with Cyclosporin A pharmacokinetics in renal transplant recipients: A meta-analysis. Wang CE; Lu KP; Chang Z; Guo ML; Qiao HL Gene; 2018 Jul; 664():44-49. PubMed ID: 29678659 [TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients. Chen B; Shi HQ; Liu XX; Zhang WX; Lu JQ; Xu BM; Chen H J Clin Pharm Ther; 2017 Dec; 42(6):679-688. PubMed ID: 28833329 [TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Hesselink DA; van Gelder T; van Schaik RH; Balk AH; van der Heiden IP; van Dam T; van der Werf M; Weimar W; Mathot RA Clin Pharmacol Ther; 2004 Dec; 76(6):545-56. PubMed ID: 15592326 [TBL] [Abstract][Full Text] [Related]
12. Impact of Donor and Recipient Shao J; Wang C; Fu P; Chen F; Zhang Y; Wei J Ann Pharmacother; 2020 Jul; 54(7):652-661. PubMed ID: 31888346 [No Abstract] [Full Text] [Related]
13. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Miao LY; Huang CR; Hou JQ; Qian MY Biopharm Drug Dispos; 2008 Jan; 29(1):1-5. PubMed ID: 17941052 [TBL] [Abstract][Full Text] [Related]
14. A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients. Falck P; Midtvedt K; Vân Lê TT; Storehagen L; Holdaas H; Hartmann A; Asberg A Clin Pharmacokinet; 2009; 48(9):615-23. PubMed ID: 19725595 [TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119 [TBL] [Abstract][Full Text] [Related]
16. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Han N; Yun HY; Hong JY; Kim IW; Ji E; Hong SH; Kim YS; Ha J; Shin WG; Oh JM Eur J Clin Pharmacol; 2013 Jan; 69(1):53-63. PubMed ID: 22660440 [TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic study of cyclosporine based on NONMEM in Chinese liver transplant recipients. Sun B; Li XY; Gao JW; Rui JZ; Guo YK; Peng ZH; Liu GL Ther Drug Monit; 2010 Dec; 32(6):715-22. PubMed ID: 21068646 [TBL] [Abstract][Full Text] [Related]
18. CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics. Song J; Kim MG; Choi B; Han NY; Yun HY; Yoon JH; Oh JM Ann Pharmacother; 2012 Sep; 46(9):1141-51. PubMed ID: 22947591 [TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. Li D; Lu W; Zhu JY; Gao J; Lou YQ; Zhang GL J Clin Pharm Ther; 2007 Oct; 32(5):505-15. PubMed ID: 17875118 [TBL] [Abstract][Full Text] [Related]
20. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. Yates CR; Zhang W; Song P; Li S; Gaber AO; Kotb M; Honaker MR; Alloway RR; Meibohm B J Clin Pharmacol; 2003 Jun; 43(6):555-64. PubMed ID: 12817518 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]